New monoclonal antibody therapy significantly lowers patient triglyceride levels
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels.
Read original article on The Medical News →Related news
-
Two-year study will examine how gender-affirming hormone therapy affects energy use and blood vessel function
United Kingdom
-
Study challenges long-held fears about overactive bladder drugs and dementia
United Kingdom
-
Stanford study challenges long-held dogma on causes of concussions
United Kingdom
-
Cluster headache linked to pronounced levels of burnout symptoms
United Kingdom
-
Could a daily supplement keep blood vessels healthier as we age?
United Kingdom
-
Why obesity affects males and females differently
United Kingdom
-
Your brain may map emotional concepts onto a hexagonal grid, new study suggests
United Kingdom
-
In phase 2 trial, novel therapy significantly reduced triglyceride levels
United Kingdom